Statins in stroke prevention: what an internist should know
Autor: | María Dolores Jiménez Hernández, María del Carmen Fernández Moreno, José Manuel López Chozas, Luis Castilla Guerra |
---|---|
Rok vydání: | 2006 |
Předmět: |
medicine.medical_specialty
Alternative medicine Hyperlipidemias chemistry.chemical_compound Epidemiology Internal Medicine Medicine Animals Humans cardiovascular diseases Intensive care medicine Stroke business.industry Cholesterol medicine.disease Coronary heart disease chemistry Stroke prevention Practice Guidelines as Topic Physical therapy Etiology lipids (amino acids peptides and proteins) Observational study Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
Zdroj: | European journal of internal medicine. 19(1) |
ISSN: | 1879-0828 |
Popis: | Historically, the etiological link between hypercholesterolemia and stroke has been less clear than for coronary heart disease. The lack of association between cholesterol levels and stroke in most epidemiological and observational studies has brought about this controversy. Many recent, long-term clinical studies have confirmed that statin therapy results in a reduced risk of strokes, even in so-called “normocholesterolemic” patients. The magnitude of the effect is great. A large-scale analysis of more than 90,000 individuals showed that every 10% reduction in the concentration of LDL-cholesterol reduces the risk of stroke by 15.6%. The positive effect of statins on stroke depends mainly on LDL cholesterol reduction, but other non-lipid mechanisms, so-called “pleiotropic” effects, have been shown to play a role. This review seeks to summarize the role of statins in stroke prevention. Despite the fact that our understanding of the benefits of statins in stroke prevention is still evolving, we find marked room for improvement in stroke risk factor management. Internists must face this challenge and integrate this new knowledge into their daily clinical practice. |
Databáze: | OpenAIRE |
Externí odkaz: |